Literature DB >> 11738470

Evidence for a role for transglutaminase in Huntington's disease and the potential therapeutic implications.

Marcela V Karpuj1, Mark W Becher, Lawrence Steinman.   

Abstract

Transglutaminase (TGase) activity is increased in affected regions of brains from patients with Huntington's disease (HD). TGase activity is particularly elevated in the nucleus compared with the cytoplasm from these brains. Gamma-glutaminyl-lysyl cross-links have been detected in nuclear inclusions in HD brain, indicating that TGase may play a prominent role in the aggregation of huntingtin (htt). Attempts to ameliorate experimental disease, via inhibition of TGase in transgenic models of HD in mice, are under investigation.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11738470     DOI： 10.1016/s0197-0186(01)00060-2

Source DB:  PubMed          Journal:  Neurochem Int        ISSN： 0197-0186            Impact factor:   3.921


  13 in total

1.  Therapeutic effects of cystamine in a murine model of Huntington's disease.

Authors:  Alpaslan Dedeoglu; James K Kubilus; Thomas M Jeitner; Samantha A Matson; Misha Bogdanov; Neil W Kowall; Wayne R Matson; Arthur J L Cooper; Rajiv R Ratan; M Flint Beal; Steven M Hersch; Robert J Ferrante
Journal:  J Neurosci       Date:  2002-10-15       Impact factor: 6.167

2.  Structural characterization of transglutaminase-catalyzed cross-linking between glyceraldehyde 3-phosphate dehydrogenase and polyglutamine repeats.

Authors:  Margherita Ruoppolo; Stefania Orrù; Simona Francese; Ivana Caputo; Carla Esposito
Journal:  Protein Sci       Date:  2003-01       Impact factor: 6.725

3.  Striatal expression of a calmodulin fragment improved motor function, weight loss, and neuropathology in the R6/2 mouse model of Huntington's disease.

Authors:  Ying Dai; Nichole L Dudek; Qian Li; Stephen C Fowler; Nancy A Muma
Journal:  J Neurosci       Date:  2009-09-16       Impact factor: 6.167

Review 4.  Transglutaminase is a therapeutic target for oxidative stress, excitotoxicity and stroke: a new epigenetic kid on the CNS block.

Authors:  Manuela Basso; Rajiv R Ratan
Journal:  J Cereb Blood Flow Metab       Date:  2013-04-10       Impact factor: 6.200

Review 5.  Current Drug Repurposing Strategies for Rare Neurodegenerative Disorders.

Authors:  Sweta Shah; Marc Marie Dooms; Sofia Amaral-Garcia; Mariana Igoillo-Esteve
Journal:  Front Pharmacol       Date:  2021-12-21       Impact factor: 5.810

6.  Tissue transglutaminase-induced aggregation of alpha-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies.

Authors:  Eunsung Junn; Ruben D Ronchetti; Martha M Quezado; Soo-Youl Kim; M Maral Mouradian
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-07       Impact factor: 11.205

7.  Neuroprotective effects of calmodulin peptide 76-121aa: disruption of calmodulin binding to mutant huntingtin.

Authors:  Nichole L Dudek; Ying Dai; Nancy A Muma
Journal:  Brain Pathol       Date:  2009-03-10       Impact factor: 6.508

8.  Induction of pathogenic sets of genes in macrophages and neurons in NeuroAIDS.

Authors:  Eleanor S Roberts; Michelle A Zandonatti; Debbie D Watry; Lisa J Madden; Steven J Henriksen; Michael A Taffe; Howard S Fox
Journal:  Am J Pathol       Date:  2003-06       Impact factor: 4.307

9.  Transglutaminase inhibition protects against oxidative stress-induced neuronal death downstream of pathological ERK activation.

Authors:  Manuela Basso; Jill Berlin; Li Xia; Sama F Sleiman; Brendan Ko; Renee Haskew-Layton; Eunhee Kim; Marc A Antonyak; Richard A Cerione; Siiri E Iismaa; Dianna Willis; Sunghee Cho; Rajiv R Ratan
Journal:  J Neurosci       Date:  2012-05-09       Impact factor: 6.167

Review 10.  Huntington's disease.

Authors:  Marcy E MacDonald; Silvia Gines; James F Gusella; Vanessa C Wheeler
Journal:  Neuromolecular Med       Date:  2003       Impact factor: 4.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.